menu
    • menu
    [{"orgOrder":0,"company":"CSPC-NBP Pharmaceutical","sponsor":"CSPC-NBP Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Butylphthalide","moa":"Mitochondrial dysfunction","graph1":"Neurology","graph2":"Phase III","graph3":"CSPC-NBP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSPC-NBP Pharmaceutical \/ CSPC-NBP Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CSPC-NBP Pharmaceutical \/ CSPC-NBP Pharmaceutical"},{"orgOrder":0,"company":"CSPC-NBP Pharmaceutical","sponsor":"CSPC-NBP Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Butylphthalide","moa":"Mitochondrial dysfunction","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSPC-NBP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC-NBP Pharmaceutical \/ CSPC-NBP Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CSPC-NBP Pharmaceutical \/ CSPC-NBP Pharmaceutical"},{"orgOrder":0,"company":"CSPC-NBP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"n-Butylphthalide","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"CSPC-NBP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"CSPC-NBP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC-NBP Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"CSPC-NBP Pharmaceutical","sponsor":"Conjupro Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"n-Butylphthalide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CSPC-NBP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"CSPC-NBP Pharmaceutical \/ CSPC-NBP Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"CSPC-NBP Pharmaceutical \/ CSPC-NBP Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by CSPC-NBP Pharmaceutical

    Menu

    CSPC-NBP Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CSPC-NBP Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CSPC-NBP Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Butylphthalide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Conjupro Biotherapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

                            Details : N-Butylphthalide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 19, 2020

                            Lead Product(s) : Butylphthalide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Conjupro Biotherapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CSPC-NBP Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CSPC-NBP Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Butylphthalide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Capital Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia

                            Details : Butylphthalide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dementia, Vascular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 15, 2019

                            Lead Product(s) : Butylphthalide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Capital Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CSPC-NBP Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CSPC-NBP Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Butylphthalide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NBP in Adult Patients With Acute Ischemic Stroke (AIS)

                            Details : N-Butylphthalide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Androgen-Insensitivity Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2016

                            Lead Product(s) : Butylphthalide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CSPC-NBP Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CSPC-NBP Pharmaceutical

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Butylphthalide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Jinling Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting

                            Details : Butylphthalide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Restenosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 29, 2011

                            Lead Product(s) : Butylphthalide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Jinling Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth